SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?


To: Miljenko Zuanic who wrote (441)11/6/2018 10:13:11 AM
From: Miljenko Zuanic  Respond to of 507
 
To comment further (maybe it will make me fill better), it is BMY who rushed trough escalation phase of PIVOT02 (they were involved almost from start, and with full access of the preclinical-PK), due to Keytruda pressure. Now, the main Qs are....can 214 make difference in NSCLC (1L and 2L-refractory)????